Thermo Fisher Scientific Inc. $TMO Shares Sold by Horizon Investment Services LLC

Horizon Investment Services LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 57.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 905 shares of the medical research company’s stock after selling 1,221 shares during the period. Horizon Investment Services LLC’s holdings in Thermo Fisher Scientific were worth $367,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Souders Financial Advisors purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $245,000. Golden State Wealth Management LLC increased its stake in Thermo Fisher Scientific by 6.6% during the second quarter. Golden State Wealth Management LLC now owns 1,900 shares of the medical research company’s stock worth $770,000 after acquiring an additional 117 shares during the last quarter. HORAN Wealth LLC purchased a new stake in Thermo Fisher Scientific in the second quarter valued at $2,583,000. Waverton Investment Management Ltd increased its position in shares of Thermo Fisher Scientific by 11.8% during the 2nd quarter. Waverton Investment Management Ltd now owns 665,000 shares of the medical research company’s stock worth $269,521,000 after purchasing an additional 70,271 shares during the last quarter. Finally, Horan Securities Inc. lifted its position in Thermo Fisher Scientific by 7.8% in the second quarter. Horan Securities Inc. now owns 524 shares of the medical research company’s stock valued at $212,000 after buying an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,420 shares of company stock worth $19,980,884 in the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $566.47 on Friday. The firm has a fifty day moving average price of $516.99 and a 200 day moving average price of $461.35. The stock has a market cap of $212.83 billion, a PE ratio of 32.73, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the previous year, the company posted $5.28 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has initiated a stock buyback program on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Wells Fargo & Company increased their target price on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Barclays upped their target price on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Finally, Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $601.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.